242 related articles for article (PubMed ID: 36485089)
1. Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?
Haddad FG; Short NJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):213-217. PubMed ID: 36485089
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
Jabbour E; Haddad FG; Short NJ; Kantarjian H
JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222
[TBL] [Abstract][Full Text] [Related]
3. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
4. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
Short NJ; Kantarjian H; Jabbour E; Ravandi F
Best Pract Res Clin Haematol; 2017 Sep; 30(3):193-200. PubMed ID: 29050692
[TBL] [Abstract][Full Text] [Related]
5. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
6. [Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era].
Dobashi N
Rinsho Ketsueki; 2020; 61(9):1227-1235. PubMed ID: 33162520
[TBL] [Abstract][Full Text] [Related]
7. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
8. Treatment de-escalation in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens.
Haddad FG; Sawyers J; Short NJ
Ther Adv Hematol; 2023; 14():20406207231151294. PubMed ID: 36755897
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.
Jabbour E; DerSarkissian M; Duh MS; McCormick N; Cheng WY; McGarry LJ; Souroutzidis A; Huang H; O'Brien S; Ravandi F; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):257-265. PubMed ID: 29519619
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Abou Dalle I; Jabbour E; Short NJ; Ravandi F
Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
12. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
16. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts.
Ganguly S; Sasi A; Pushpam D; Bakhshi S
Indian J Pediatr; 2024 Jan; 91(1):37-46. PubMed ID: 37632689
[TBL] [Abstract][Full Text] [Related]
17. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
[TBL] [Abstract][Full Text] [Related]
18. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
[TBL] [Abstract][Full Text] [Related]
19. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
[TBL] [Abstract][Full Text] [Related]
20. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]